^
    Back
    Association details:
    Biomarker:HRAS Q61
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ESMO 2022
    Title:

    1771P - Genomic characteristics and clinical outcomes of HRAS-mutated urothelial bladder cancer

    Published date:
    09/05/2022
    Excerpt:
    Patients with HRAS-Q61 point mutations experienced worse OS and prognosis compared to HRASwt tumors when treated with checkpoint inhibitors (HR 1.45, 95% 1.01-2.10; p <0.05)...HRAS-Q61 point mutations represent a clinically relevant mutation in UBC, as evidenced by its association with worse clinical outcomes compared to HRASwt tumors. Our transcriptomic analysis suggests HRAS-Q61 mutations were associated with lower response to immunotherapy...